Lonza Group

Lonza Group

Type	Public
Traded as	SIX: LONN
Key people	Pierre-Alain Ruffieux (CEO)
Industry	Pharmaceuticals, Biotechnology
Products	Active pharmaceutical ingredients, Biopharmaceuticals, Specialty chemicals
Revenue	CHF 4.5 billion (2020)
Employees	15,000 (2020)
Website	[www.lonza.com Official website]

Lonza Group is a leading global provider of integrated healthcare solutions, specializing in the development, manufacturing, and commercialization of pharmaceutical and biotechnology products. Founded in 1897 in the Swiss Alps, Lonza has grown to become a key player in the life sciences industry, with a focus on innovation and sustainability.

History

Lonza was established in 1897 in the small Swiss town of Gampel, initially focusing on the production of electricity and calcium carbide. Over the years, the company expanded its operations into the chemical and pharmaceutical sectors. In the 1970s, Lonza shifted its focus towards biotechnology, which has since become a core component of its business strategy.

In 1999, Lonza was spun off from Alusuisse-Lonza Group Ltd and became an independent company listed on the Swiss Stock Exchange. Since then, Lonza has made several strategic acquisitions to enhance its capabilities in the life sciences sector, including the acquisition of Capsugel in 2017, a leader in capsule-based drug delivery solutions.

Operations

Lonza operates through two main segments: Pharma & Biotech and Specialty Ingredients.

Pharma & Biotech

The Pharma & Biotech segment focuses on the development and manufacture of active pharmaceutical ingredients (APIs), biopharmaceuticals, and cell and gene therapies. Lonza provides end-to-end solutions for its clients, from early-stage development to commercial manufacturing. The company is known for its expertise in mammalian cell culture, microbial fermentation, and chemical synthesis.

Specialty Ingredients

The Specialty Ingredients segment offers a wide range of products, including microbial control solutions, personal care ingredients, and nutritional supplements. Lonza's microbial control solutions are used in various industries, such as water treatment, paints and coatings, and wood protection.

Research and Development

Lonza invests significantly in research and development to drive innovation and maintain its competitive edge. The company collaborates with academic institutions, research organizations, and industry partners to advance its technological capabilities and develop new products. Lonza's R&D efforts are focused on areas such as biologics, cell and gene therapy, and sustainable chemistry.

Sustainability

Lonza is committed to sustainability and has implemented various initiatives to reduce its environmental impact. The company aims to minimize waste, reduce energy consumption, and promote the use of renewable resources. Lonza also focuses on sustainable sourcing and ethical business practices.

Also see

• Biotechnology
• Pharmaceutical industry
• Active pharmaceutical ingredient
• Biopharmaceutical
• Cell therapy
• Gene therapy

Template:Biotechnology companies